These risks include, but are not limited to, the following:•Our business is dependent on the successful development, regulatory approval and commercialization of our product candidates,
delay, limitation or denial of any regulatory approval would adversely impact commercialization, our potential to generate revenue, our business and our operating results.•UCB substantially controls the governance of our collaboration, and may make decisions regarding product development, regulatory
contractual obligations and with all regulatory requirements applicable to our product candidates or any future product candidates or approved products, if any;•the ability of third parties with whom we contract to manufacture clinical trial and commercial supplies of our product candidates or
amount and timing of our future funding requirements will depend on many factors, including:•the timing, rate of progress and cost of any preclinical and clinical trials and other product development activities for our current
and any future product candidates that we develop, in-license or acquire;•the results of the clinical trials for our product candidates in the United States and any foreign countries;•the timing of, and the costs involved in, FDA approval and any foreign regulatory approval of our product candidates, if at all;•the number and characteristics of any additional future product candidates we develop or acquire;•our ability to establish and maintain strategic collaborations, licensing, co-promotion or other arrangements and the terms and timing
enrollment and completion of clinical trials, including as a result of regulatory requirements, could substantially increase our product development costs.
conduct additional trials and studies, increased expenses associated with the services of our CROs and other third parties or other reasons.Clinical drug development for our product candidates is very expensive, time-consuming and
Our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates, which could prevent or delay regulatory approval and commercialization.Clinical drug development for our product candidates is very expensive, time-consuming and difficult to design and implement, and its
with applicable FDA or other regulatory requirements relating to the conduct of clinical trials or the handling, storage, security and recordkeeping for drug and biologic products;•scheduling conflicts with participating clinicians and clinical institutions;•failure to design appropriate clinical trial protocols;•inability or unwillingness of medical investigators to follow our clinical protocols;•difficulty in maintaining contact with subjects during or after treatment, which may result in incomplete data; or•insufficient data to support regulatory approval.18Table of ContentsIn the case of our topical product candidates, we are seeking to deliver sufficient concentrations of the active pharmaceutical ingredient, or API, through the skin barrier to the
labeling or specifications of our current or future product candidates;•the FDA or the applicable foreign regulatory agency may require clinical trials in pediatric patients in order to establish
post-approval clinical trials;•the FDA or the applicable foreign regulatory agency also may approve our current or any future product candidates for a more limited
successful commercialization of our product candidates;20Table of Contents•the FDA or the applicable foreign regulatory body may not approve of the manufacturing processes, controls or facilities of
operating results and financial condition will be adversely affected, which may delay, prevent or limit our ability to generate revenue and continue our business.According to Decision Resources, Enbrel, Humira and Stelara, injectable biologics for the treatment of moderate-to-severe plaque psoriasis, achieved aggregate worldwide sales of
inspection costs, required due dates for specific actions and penalties for noncompliance;•issue warning letters, show cause notices or untitled letters describing alleged violations, which may be publicly available;•commence criminal investigations and prosecutions;•impose injunctions, suspensions or revocations of necessary approvals or other licenses;•impose other civil or criminal penalties;•suspend any ongoing clinical trials;•delay or refuse to approve pending applications or supplements to approved applications filed by us or our potential partners;•refuse to permit drugs or precursor chemicals to be imported or exported to or from the United States;26Table of Contents•suspend or impose restrictions on operations, including costly new manufacturing requirements; or•seize or detain products or require us or our partners to initiate a product recall.The
our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and could harm our business, financial condition, operating results and prospects.If any of our product candidates are approved for marketing and we are found to have improperly
of clinical trials; the likelihood of approval by the FDA or other regulatory authorities; the potential market for the subject product candidate; the costs and complexities of manufacturing and
either on our own or through collaborations with one or more third parties, would harm our business, financial condition, operating results and prospects.Our failure to successfully in-license, acquire, develop and market additional product candidates or
any product candidate that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical testing and approval by the FDA and